deltatrials

Acorda Therapeutics Clinical Trials

Sponsors / Acorda Therapeutics

Acorda Therapeutics is listed as the lead sponsor on 56 clinical trials registered with ClinicalTrials.gov. 0 trials are actively recruiting participants, 0 remain active without open enrollment, and 47 have concluded. 9 of these trials ended early via termination or withdrawal. The most common reasons cited for termination include safety concerns, slow or insufficient recruitment. The cumulative planned enrollment figure across all listed trials is 5,817 participants. All figures are drawn directly from ClinicalTrials.gov and updated as sponsors submit revisions.

56
Total Trials
0
Recruiting
0
Other Active
47
Completed
9
Terminated / Withdrawn
5,817
Total Enrollment

Termination reasons: Other56% · Safety33% · Recruitment11%

Recent Terminations

  • NCT03051607 Phase PHASE3 Stopped Jan 2018
    Idiopathic Parkinson Disease
    "New Safety Information"
  • NCT03212313 Phase PHASE1 Stopped Dec 2017
    Hepatic Impairment
    "New Safety Information"
  • NCT03200080 Phase PHASE1 Stopped Nov 2017
    Abuse Potential
    "New Safety Information"
  • NCT02422940 Phase PHASE3 Stopped Jan 2017
    Post-ischemic Stroke
  • NCT02316847 Phase PHASE2 Stopped Sep 2016
    Epilepsy
  • NCT02474407 Phase PHASE2 Stopped Jul 2016
    Refractory Epilepsy
  • NCT01750684 Phase PHASE2 Stopped May 2015
    Acute Spinal Cord Injury
    "The study was terminated by the Sponsor due to insufficient enrollment."
  • NCT01405950 Phase PHASE1 Stopped Mar 2012
    Spasticity Due to Cerebral Palsy
    "Please see 'Further study details as provided by Acorda Therapeutics' for explanation of why study stopped."
  • NCT01446575 Phase PHASE4
    Transverse Myelitis
    "This study was redesigned to be more statistically rigorous."

Top Conditions

Top Locations